EcoDrugPlus

Endothelin Receptor Type B

Ensembl ID : ENSOTSG00005032727
Gene Symbol: EDNRB
3 Cross references
192 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSOTSG00005047885
Gene Symbol: LOC112226679
3 Cross references
192 Possible Orthologues:

Endothelin-Converting Enzyme 1-Like

Ensembl ID : ENSOTSG00005029884
Gene Symbol: LOC112218563
3 Cross references
224 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSOTSG00005010872
Gene Symbol: EZH2
3 Cross references
235 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSOTSG00005042167
Gene Symbol: EGFRA
1 Cross references
206 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSOTSG00005019053
Gene Symbol: LOC112226767
3 Cross references
206 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSOTSG00005025777
Gene Symbol: EPHX2
1 Cross references
198 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSOTSG00005020385
Gene Symbol: LOC112255674
3 Cross references
203 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSOTSG00005013469
Gene Symbol: LOC112253146
3 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSOTSG00005006108
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSOTSG00005003431
Gene Symbol: ERBB3
3 Cross references
205 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSOTSG00005029394
Gene Symbol: ERBB3
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).